HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 384 filers reported holding HALOZYME THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.39 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $19,893,643 | +6.3% | 520,776 | +0.4% | 0.26% | +9.7% |
Q2 2023 | $18,718,779 | -2.1% | 518,957 | +3.7% | 0.24% | -11.9% |
Q1 2023 | $19,120,205 | -75.0% | 500,660 | -62.7% | 0.27% | -76.5% |
Q4 2022 | $76,392,745 | +43.5% | 1,342,579 | -0.3% | 1.14% | +41.3% |
Q3 2022 | $53,236,000 | -5.7% | 1,346,386 | +5.0% | 0.81% | -11.8% |
Q2 2022 | $56,430,000 | +67.6% | 1,282,492 | +51.9% | 0.91% | +121.3% |
Q1 2022 | $33,661,000 | +43.1% | 844,063 | +44.3% | 0.41% | +72.1% |
Q4 2021 | $23,519,000 | -30.4% | 584,910 | -29.6% | 0.24% | -40.1% |
Q3 2021 | $33,809,000 | +31.4% | 831,094 | +46.7% | 0.40% | +17.6% |
Q2 2021 | $25,723,000 | +35.6% | 566,459 | +24.5% | 0.34% | +21.8% |
Q1 2021 | $18,969,000 | +55.9% | 455,013 | +59.7% | 0.28% | +42.1% |
Q4 2020 | $12,170,000 | +75.5% | 284,946 | +8.0% | 0.20% | +38.7% |
Q3 2020 | $6,934,000 | +4.7% | 263,847 | +6.8% | 0.14% | -11.8% |
Q2 2020 | $6,623,000 | +53.7% | 247,032 | +3.1% | 0.16% | +11.8% |
Q1 2020 | $4,309,000 | – | 239,531 | – | 0.14% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |
Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |